Finance

Lists
Why is PMVP down 2,94%?
Dive Deeper
PMVP:NASDAQ
PMV Pharmaceuticals Inc
1,32 $
-2,94%
(-0,040) 1D
22 қаз., 14:55:13 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PMVP...
Open
1,36 $
High
1,37 $
Low
1,31 $
Mkt. cap
99,68 млн
Avg. vol.
792,99 м.
Volume
97,59 мың
52-wk high
1,91 $
52-wk low
1,02 $
EPS
-1,41 $
Beta
1,36
Shares outstanding
75,51 млн
No. of employees
54
Open
1,36 $
High
1,37 $
Low
1,31 $
Mkt. cap
99,68 млн
Avg. vol.
792,99 м.
Volume
97,59 мың
52-wk high
1,91 $
52-wk low
1,02 $
EPS
-1,41 $
Beta
1,36
Shares outstanding
75,51 млн
No. of employees
54
News stories
From web sources and news partners
About PMV Pharmaceuticals Inc
CEO-
Employees54
Founded2013
Headquarters-
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to PMVP in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PMVP in the last 3 months.
Highest
Current 1,32 $
5,00 $ (+278,79%)
Average
4,20 $ (+218,18%)
Lowest
3,00 $ (+127,27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
5,00 $
+278,8%
09/08/2026
Unknown Analyst
Craig-Hallum
Buy
Reiterated
4,00 $
+203%
09/01/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
4,00 $
+203%
09/01/2026
Jay Olson
Oppenheimer
Buy
Reiterated
5,00 $
+278,8%
09/01/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
5,00 $
+278,8%
09/01/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Reiterated
3,00 $
+127,3%
08/17/2026
Rick Bienkowski
Ladenburg Thalmann & Co.
Buy
Reiterated
3,00 $
+127,3%
08/17/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/12/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
4,00 $
+203%
11/13/2025
Last report
2026 ж. 14 там.
Fiscal period
Q2 2026
-0,34 $ / -0,40 $
+15,00%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18,21 млн
15,83 млн
15,33 млн
14,68 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,31 млн
3,42 млн
3,69 млн
4,20 млн
Operating expense
22,52 млн
19,24 млн
19,02 млн
18,88 млн
Total operating expenses
22,52 млн
19,24 млн
19,02 млн
18,88 млн
Operating income
-22,52 млн
-19,24 млн
-19,02 млн
-18,88 млн
Other non operating income
-23,00 мың
-1,00 мың
1,00 мың
10,00 мың
EBT including unusual items
-21,06 млн
-18,01 млн
-18,04 млн
-18,08 млн
EBT excluding unusual items
-21,06 млн
-18,01 млн
-18,04 млн
-18,08 млн
Income tax expense
-6,00 мың
26,00 мың
-
3,00 мың
Effective tax rate
0,03%
-0,14%
-
-0,02%
Other operating expenses
-
-
-
-
Net income
-21,06 млн
-18,04 млн
-18,04 млн
-18,09 млн
Net profit margin
-
-
-
-
Earnings per share
-0,40
-0,34
-0,34
-0,34
Interest and investment income
1,48 млн
1,23 млн
980,00 м.
788,00 м.
Interest expense
-
-
-
-
Net interest expenses
1,48 млн
1,23 млн
980,00 м.
788,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-22,49 млн
-19,21 млн
-18,98 млн
-18,86 млн
Gain or loss from assets sale
-1,00 мың
-
-
25,00 мың
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары